Identification of PSMD2 as a promising biomarker for pancreatic cancer patients based on comprehensive bioinformatics and in vitro studies
Xiuxue Feng, Qiang Liu, Huikai Li, Jing Yang, Enqiang Linghu · 2024
Read Identification of PSMD2 as a promising biomarker for pancreatic cancer patients based on comprehensive bioinformatics and in vitro studies by Xiuxue Feng, Qiang Liu, Huikai Li, Jing Yang, Enqiang Linghu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11616520.txt.
Description
Xiuxue Feng and co-authors single out a proteasome part, PSMD2, as a warning sign and possible target in pancreatic cancer, in this 2024 paper. Most proteasome subunit genes ran hot in tumor tissue from a large atlas. Two of them tracked with worse survival when highly expressed. The team profiled how the pair relates to immune signals, drug response, and tumor pathways.
Cell tests separated the twins. Silencing PSMD2 slowed cancer cell growth, raised cell death, and made the standard drug gemcitabine bite harder; boosting it did the reverse. The protein works by switching on the AKT growth pathway, and an AKT blocker hit high-PSMD2 cells hardest, undoing its push. The authors propose PSMD2 as a marker for who might benefit from AKT drugs.
Catalog record
| CREATOR | Xiuxue Feng, Qiang Liu, Huikai Li, Jing Yang, Enqiang Linghu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |